ReviewExpert opinion on pharmacotherapy2016
Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?
Review in Expert opinion on pharmacotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 144 citations in OpenAlex.
- Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.Leukemia research · 2018Trial
- Predictive value of extra-rectal colonization and theInfection prevention in practice · 2026Article
- Fosfomycin susceptibility and molecular detection of fosA-mediated resistance among gram-negative uropathogens from a tertiary care hospital in Lucknow, India.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Molecular epidemiology of OXA-1054, a novel carbapenem-hydrolysing Class D β-lactamase, in Enterobacteriaceae isolated from wastewaters.npj antimicrobials and resistance · 2026Article
- Genetic Insights into Colistin Resistance in Carbapenem-ResistantInfection & chemotherapy · 2026Article
- Bacterial distribution and drug resistance patterns of urinary tract infection in tuberculosis patients: a 5-year retrospective study.Frontiers in microbiology · 2026Article
- Limits of rapid diagnostics: genomic and structural insights into OXA-48-like mediated carbapenem resistance inFrontiers in microbiology · 2026Article
- Chelerythrine potentiates meropenem activity against NDM-producing carbapenem-resistant Enterobacteriaceae.Frontiers in veterinary science · 2026Article
- Potential role of avibactam in restoring susceptibility in Escherichia coli with two copies of blaScientific reports · 2025Article
- Ceftazidime-avibactam treatment dilemma of blaAnnals of clinical microbiology and antimicrobials · 2024Article
- Changing Genotypic Distribution, Antimicrobial Susceptibilities, and Risk Factors of Urinary Tract Infection Caused by Carbapenemase-ProducingAnnals of laboratory medicine · 2024Article
- Genome drafting of nosocomial infection CREFrontiers in cellular and infection microbiology · 2024Article
- In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates.Microorganisms · 2023Article
- The Use and Effectiveness of Ceftazidime-Avibactam in Real-World Clinical Practice: EZTEAM Study.Infectious diseases and therapy · 2023Article
- A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects.Molecules (Basel, Switzerland) · 2023Review
- Risk factors and molecular epidemiology of fecal carriage of carbapenem resistant Enterobacteriaceae in patients with liver disease.Annals of clinical microbiology and antimicrobials · 2023Article
- Benefits and Safety of Empiric Antibiotic Treatment Active Against KPC-Infection and drug resistance · 2023Article
- Outbreak of Klebsiella pneumoniae ST11 Resistant To Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina.Microbiology spectrum · 2022Article
- Factors influencing decision making and antibiotic prescribing patterns for the treatment of carbapenem-resistantTranslational and clinical pharmacology · 2022Article
- A Literature Overview of Secondary Peritonitis Due to Carbapenem-Resistant Enterobacterales (CRE) in Intensive Care Unit (ICU) Patients.Antibiotics (Basel, Switzerland) · 2022Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
introductionFor the past three decades, carbapenems played a central role in our antibiotic armamentarium, trusted to effectively treat infections caused by drug-resistant bacteria. The utility of this class of antibiotics has been compromised by the emergence of resistance especially among Enterobacteriaceae. AREAS COVERED: We review the current mainstays of pharmacotherapy against infections caused by carbapenem-resistant Enterobacteriaceae (CRE) including tigecycline, aminoglycosides, and rediscovered 'old' antibiotics such as fosfomycin and polymyxins, and discuss their efficacy and potential toxicity. We also summarize the contemporary clinical experience treating CRE infections with antibiotic combination therapy. Finally, we discuss ceftazidime/avibactam and imipenem/relebactam, containing a new generation of beta-lactamase inhibitors, which may offer alternatives to treat CRE infections. We critically evaluate the published literature, identify relevant clinical trials and review documents submitted to the United States Food and Drug Administration. EXPERT OPINION: Defining the molecular mechanisms of resistance and applying insights about pharmacodynamic and pharmacokinetic properties of antibiotics, in order to maximize the impact of old and new therapeutic approaches should be the new paradigm in treating infections caused by CRE. A concerted effort is needed to carry out high-quality clinical trials that: i) establish the superiority of combination therapy vs. monotherapy; ii) confirm the role of novel beta-lactam/beta-lactamase inhibitor combinations as therapy against KPC- and OXA-48 producing Enterobacteriaceae; and, iii) evaluate new antibiotics active against CRE as they are introduced into the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.